Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Fuhr

Showing results (51-60 of 136) with videos related to

Pageof 14
Sort By:
The Journal of Urology|May 15, 2013
Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical studyPetra Krause, Uwe Fuhr, Jörg Schnitker, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 23, 2019
Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studiesOliver Scherf-Clavel, Martina Kinzig, Marc S Stoffel, et al.
Clinical Pharmacology and Therapeutics|February 25, 2025
A Joint Pharmacometric Model of Iohexol and Creatinine Administered through a Meat Meal to Assess GFR and Renal OCT2/MATE ActivityZhendong Chen, Qian Dong, Charalambos Dokos, et al.
European Journal of Clinical Pharmacology|December 17, 2008
Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?Alexander Jetter, Martina Kinzig, Michael Rodamer, et al.
Drug Metabolism and Pharmacokinetics|November 30, 2015
Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhalerSebastian Frechen, Ahmed Abbas Suleiman, Ali Mohammad Nejad Sigaroudi, et al.
Pharmacogenomics|February 29, 2008
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acidsJulia Kirchheiner, Ingolf Meineke, Uwe Fuhr, et al.
Clinical Pharmacology and Therapeutics|October 4, 2005
The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteersAlexander Jetter, Andreas Lazar, Edgar Schömig, et al.
European Journal of Clinical Pharmacology|February 18, 2011
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)Natig Gassanov, Nasser Semmo, Mariam Semmo, et al.
Clinical Pharmacokinetics|August 22, 2021
Clinical Pharmacokinetics and Pharmacodynamics of CefiderocolMuhammad Bilal, Lobna El Tabei, Sören Büsker, et al.
European Journal of Clinical Pharmacology|June 30, 2011
Clinical impact of fluvoxamine-mediated long QTU syndromeAmir M Nia, Kristina M Dahlem, Natig Gassanov, et al.
Pageof 14

Showing results (51-60 of 136) with videos related to

Sort By:
Pageof 14
The Journal of Urology|May 15, 2013
Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical studyPetra Krause, Uwe Fuhr, Jörg Schnitker, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 23, 2019
Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studiesOliver Scherf-Clavel, Martina Kinzig, Marc S Stoffel, et al.
Clinical Pharmacology and Therapeutics|February 25, 2025
A Joint Pharmacometric Model of Iohexol and Creatinine Administered through a Meat Meal to Assess GFR and Renal OCT2/MATE ActivityZhendong Chen, Qian Dong, Charalambos Dokos, et al.
European Journal of Clinical Pharmacology|December 17, 2008
Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?Alexander Jetter, Martina Kinzig, Michael Rodamer, et al.
Drug Metabolism and Pharmacokinetics|November 30, 2015
Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhalerSebastian Frechen, Ahmed Abbas Suleiman, Ali Mohammad Nejad Sigaroudi, et al.
Pharmacogenomics|February 29, 2008
Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acidsJulia Kirchheiner, Ingolf Meineke, Uwe Fuhr, et al.
Clinical Pharmacology and Therapeutics|October 4, 2005
The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteersAlexander Jetter, Andreas Lazar, Edgar Schömig, et al.
European Journal of Clinical Pharmacology|February 18, 2011
Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)Natig Gassanov, Nasser Semmo, Mariam Semmo, et al.
Clinical Pharmacokinetics|August 22, 2021
Clinical Pharmacokinetics and Pharmacodynamics of CefiderocolMuhammad Bilal, Lobna El Tabei, Sören Büsker, et al.
European Journal of Clinical Pharmacology|June 30, 2011
Clinical impact of fluvoxamine-mediated long QTU syndromeAmir M Nia, Kristina M Dahlem, Natig Gassanov, et al.
Pageof 14